Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Efficacy and Safety of WPQW Granule for Overlap of NERD and IBS-D

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of WPQW Granule for Overlap of Non-Erosive Reflux Disease(NERD) and Diarrhea Predominant Diarrhea Irritable Bowel Syndrome(IBS-D)

Non-erosive reflux disease(NERD)and Diarrhea-Predominant Irritable Bowel Syndrome(IBS-D)are both the common refractory gastrointestinal diseases. Patients, who suffered from overlapping symptoms of NERD and IBS-D, present more serious symptom manifestation, anxiety, and worse life quality than those with solely disease. There is lack of effective treatment for overlapping gastrointestinal symptoms. Traditional Chinese Medicine (TCM) syndrome differentiation and treatment has the advantages of overall regulation and individualized treatment, but lack of high-level evidence. The purpose of this study is to evaluate the efficacy and safety of WPQW granule for the treatment of NERD overlapping IBS-D.

Přehled studie

Detailní popis

Gastroesophageal reflux disease (GERD) is a chronic relapsing acid-peptic disorder that is caused by the reflux of gastric or duodenum content. Non-erosive reflux disease(NERD), which account for 70%, is the most common type of GERD in the Asian population. Diarrhea-Predominant Irritable Bowel Syndrome(IBS-D)is the mainly subtype of IBS, and the prevalence was found to be 46% in IBS. Both diseases aforementioned are common and frequent chronic diseases in the world, and the pathogenesis of which has not been fully defined. Current studies have shown that GERD can present in patients with IBS, vice versa. Up to 79% of patients with IBS co-exist with GERD-like symptoms, and 71% of patients with GERD co-exist with IBS-like symptoms. For those patients, they suffer from more serious symptom manifestation, anxiety, and worse life quality those with solely disease. The diagnosis and treatment of Functional gastrointestinal disorders (FGIDs) mostly based on the idea of segmental diagnosis and single-target therapy in modern medicine, and there is lack of effective treatment for overlapping gastrointestinal symptoms. The advantages of holistic diagnosis therapy and individualized treatment in Traditional Chinese Medicine(TCM)have attracted international attention, but there is still lack of high-level evidence-based medical evidence for the treatment of symptom overlap in FGIDs in TCM. In this study, we propose to conduct a multicenter, randomized, double-blind, placebo-controlled clinical study of WPQW granule for the treatment of NERD overlapping IBS-D to evaluate the efficacy and safety of WPQW granule with the aim of obtaining high-level evidence-based medical evidence.

Typ studie

Intervenční

Zápis (Očekávaný)

216

Fáze

  • Raná fáze 1

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

  • Jméno: Fengyun Wang, M.D
  • Telefonní číslo: +86(010)62835248
  • E-mail: wfy811@163.com

Studijní místa

    • Beijing
      • Beijing, Beijing, Čína, 100091
        • Nábor
        • Xiyuan Hospital of China Academy of Chinese Medical Sciences
        • Kontakt:
          • Fengyun Wang, M.D
          • Telefonní číslo: +86(010)62835248
          • E-mail: wfy811@163.com

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 70 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  1. Patients diagnosed with NERD and IBS-D simultaneously
  2. Patients who present cardinal symptoms like reflux, heartburn, abdominal pain/bloating, diarrhea, etc
  3. Patients diagnosed with syndrome of intermingled cold and heat of traditional Chinese medicine
  4. Patients have informed consent and are willing to receive corresponding treatment

Exclusion Criteria:

  1. Patients with hiatal hernia
  2. Patients with upper gastrointestinal bleeding, peptic ulcer, gastrointestinal tumor, chronic atrophic gastritis with dysplasia
  3. Patients with other serious organic diseases, such as acute cardiovascular disease, acute and chronic pancreatitis, cirrhosis, abnormal liver function (transaminases more than 1.5 times of normal value), abnormal thyroid function, diabetes mellitus with a history of more than 10 years, chronic renal insufficiency, hematologic disorders, and hematologic disorders, etc
  4. Patients with neurological disease or psychiatric impairment like severe anxiety, depression requiring long-term drug treatment
  5. Patients who cannot stop taking acid suppressants for a long time
  6. Alcohol or drug dependency or abuse
  7. Pregnant or lactating women
  8. Patients who have a history of allergies to all the test drugs
  9. Patients who are participating in other clinical trials or have participated in other clinical trials within 3 months
  10. Patients who, in the opinion of the investigator, are not suitable to participate in clinical trial

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Trojnásobný

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Experimental group
Oral administration of WPQW granule with warm water,2 sachets each time, 3 times a day, 1.5-2 hours after a meal. The medication period was 4 weeks.
WPQW granule, 2 sachets / time, 3 times / day.
Komparátor placeba: Control group
Oral administration of WPQW granule simulant,which containing 5% WPQW granule,with warm water,2 sachets each time, 3 times a day, 1.5-2 hours after a meal. The medication period was 4 weeks.
WPQW granule simulant, 2 sachets / time, 3 times / day.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change of visual analogue scale (VAS) score of symptoms of reflux and heartburn
Časové okno: baseline, 4 weeks during treatment period, 4 weeks during follow-up period
During the medication period, the patients recorded the reflux and heartburn episodes (frequency and duration) within 24 hours per day on the symptom diary card, and VAS scores for reflux and heartburn symptoms was calculated as the mean score of each symptom in the past week. The episodes in the week before medication were used as the baseline, the mean score of any symptom decreased ≥50% from the baseline was recorded as response after weekly treatment, and the number of response weeks was considered effective if it was greater than 50% of the weeks of the whole treatment period.
baseline, 4 weeks during treatment period, 4 weeks during follow-up period
Change of visual analogue scale (VAS) score of symptoms of abdominal pain and diarrhea
Časové okno: baseline, 4 weeks during treatment period, 4 weeks during follow-up period
During the medication period, the patients recorded the of abdominal pain (pain severity and frequency) and diarrhea (stool consistency and frequency based on Bristol stool form scale) within 24 hours per day on the symptom diary card. VAS score was conducted for the most severe abdominal pain, and the mean score was calculated for each week, with the week of episodes prior to medication administration as the baseline. It was considered effective when the weekly mean score decrease of at least 30% from baseline and the days of at least once type 6 or type 7 stool Bristol stool form every week decrease of at least 30% from baseline, referring to the efficacy evaluation of the technical guidelines for clinical studies of Chinese medicine for IBS published in 2017.
baseline, 4 weeks during treatment period, 4 weeks during follow-up period

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change of traditional Chinese Medicine syndrome score
Časové okno: baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
The symptoms related to syndrome of intermingled cold and heat were scored. The cardinal symptom was scored 0, 2, 4, 6 and the secondary symptom scored 0, 1, 2, 3 respectively according to severity of each symptom. Total symptom score represented the syndrome score. Reduction in syndrome score represented Improvement.
baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
Change of 36-item short-form (SF-36) score
Časové okno: baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
Health status was evaluated by a 36-item short-form (SF-36) containing eight health concepts. If the score descends, it indicates that the patient's condition has improved.
baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
Change of FGI-checklist score
Časové okno: baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
A 20-item FGI-checklist was used to evaluate comprehensive symptom severity of Functional Gastrointestinal Disorder (FGID), which covering esophageal, dyspeptic and bowel symptoms. If the score descends, it indicates that the patient's condition has improved.
baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
Change of Hospital Anxiety and Depression Scale (HAD) score
Časové okno: baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
Hospital Anxiety and Depression Scale (HAD) score was used to evaluate the efficacy of experimental drug. Reduction in total score represented Improvement
baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

1. prosince 2021

Primární dokončení (Očekávaný)

1. května 2023

Dokončení studie (Očekávaný)

1. května 2023

Termíny zápisu do studia

První předloženo

8. května 2022

První předloženo, které splnilo kritéria kontroly kvality

10. května 2022

První zveřejněno (Aktuální)

11. května 2022

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

11. května 2022

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

10. května 2022

Naposledy ověřeno

1. prosince 2021

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit